

## **NZX/ASX Announcement**

21 March 2023

For Public Release

NZX Limited  
Wellington

## **TruScreen Rights Offer closes**

### **Results of the Rights Offer**

TruScreen advises that it has closed its 1 for 5 pro rata renounceable rights offer ("Rights Offer"), on 15 March 2023

The over subscription bookbuild price was set by the board at NZ\$0.03 or A\$0.029.

The Company raised a total of NZ\$1.6m comprising;

### **Rights Offer**

Approximately 33.7 million new shares being taken up by Eligible Shareholders from their entitlements and over subscription applications, raising approximately NZ\$1 million.

### **Placement**

As previously announced to the market, TruScreen has also placed an additional 20 million new ordinary fully paid shares at NZ\$0.03 (raising NZD\$600,000) in accordance with the 15% Placement Rule.

### **Allotment of new shares**

Settlement, allotment and trading in the new shares under the Rights Offer, and the Placement is expected to occur on 22 March 2023 under the existing ticker "TRU".

-ENDS-

This announcement has been approved by the Board.

Guy Robertson

Company Secretary

### **Ends**

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Dr Beata Edling  
Chief Executive Officer  
[beataedling@truscreen.com](mailto:beataedling@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

Julia Maguire  
Investor Relations  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/)